Even as Chinese relation, made some of the analysts to recommend an 'avoid' to the stock of Gland Pharma at first during the IPO, ever since its debut the pharma scrip has gained magnificently. And now as the Sputnik V vaccine has received an approval, the stock has been on fire.
Gland Pharma is close to double its initial issue price and on Tuesday (April 20, 2021) scaled to its fresh high of Rs. 2879 per share on the BSE. On the NSE, the stock's high made has been Rs. 2873.
The stock debuted on the bourses in November 2020 and now is quoting at nearly 92% gain in comparison to its issue price of Rs. 1500 shares apiece.
And now for the vaccination, the company has entered into collaboration with RDIF for supplying up to 252 million doses of the shots. It is also in talks with several other vaccine developers, including Pfizer, to manufacture and supply shots, said analysts at Motilal Oswal Financial Services Ltd.
Outlook for Gland Pharma stock
"We expect at $3.5 price per dose at 25-30% capacity utilisation for domestic market, Gland Pharma could add Rs1,500 crore sales (EBITDA margins 15%)" said analysts at Axis Securities Ltd. This could add incremental EPS of Rs6.4 a share and about Rs200 value per share to Gland Pharma's share price.
Multiple marketing working model
No regulatory hurdle